Nascent Biotech, Inc. (OTCMKTS:NBIO) Short Interest Update

Nascent Biotech, Inc. (OTCMKTS:NBIOGet Rating) was the recipient of a significant increase in short interest in the month of May. As of May 15th, there was short interest totalling 18,300 shares, an increase of 281.3% from the April 30th total of 4,800 shares. Based on an average daily trading volume, of 865,000 shares, the short-interest ratio is currently 0.0 days.

Shares of NBIO traded up $0.00 during midday trading on Thursday, hitting $0.12. 87,000 shares of the company traded hands, compared to its average volume of 184,148. The stock has a 50-day moving average of $0.10 and a 200-day moving average of $0.07. Nascent Biotech has a one year low of $0.04 and a one year high of $0.16.

About Nascent Biotech (Get Rating)

Nascent Biotech, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a monoclonal antibody to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as lung and breast cancer metastases to the brain; and pancreatic cancer.

Further Reading

Receive News & Ratings for Nascent Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nascent Biotech and related companies with MarketBeat.com's FREE daily email newsletter.